Allogene Therapeutics, Inc. Increase (Decrease) in Notes Payable, Current
Allogene Therapeutics, Inc. (ALLO) reported Increase (Decrease) in Notes Payable, Current of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-25.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInNotesPayableCurrent · last filed 2021-02-25
- Allogene Therapeutics, Inc. increase (decrease) in notes payable, current for the quarter ending 2018-12-31 was $1.80M.
- Allogene Therapeutics, Inc. increase (decrease) in notes payable, current for the quarter ending 2018-09-30 was $19.40M.
- Allogene Therapeutics, Inc. increase (decrease) in notes payable, current for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- Allogene Therapeutics, Inc. increase (decrease) in notes payable, current for fiscal 2019 was $21.20M, a 0.00% change from fiscal 2018.
- Allogene Therapeutics, Inc. increase (decrease) in notes payable, current for fiscal 2018 was $21.20M.
| Period end | Increase (Decrease) in Notes Payable, Current 3 month | Increase (Decrease) in Notes Payable, Current 3 month as first filed | Increase (Decrease) in Notes Payable, Current 6 month | Increase (Decrease) in Notes Payable, Current 9 month | Increase (Decrease) in Notes Payable, Current 9 month as first filed | Increase (Decrease) in Notes Payable, Current 12 month | Increase (Decrease) in Notes Payable, Current 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-02-25 | ||||||
| 2019-12-31 | $21.20M 10-K · filed 2021-02-25 | $0.00 10-K · filed 2020-02-27 | |||||
| 2018-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $21.20M derived: sum of 2 quarters · filed 2020-02-27 | $21.20M 10-K · filed 2020-02-27 | ||||
| 2018-09-30 | $19.40M 10-Q · filed 2019-11-05 | $19.40K 10-Q · filed 2018-11-21 | $19.40M 10-Q · filed 2019-11-05 | $19.40K 10-Q · filed 2018-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |